IP Library › Granted Patent US 12,735,707
Granted Patent B2
US 12,735,707 · App. 18/351,320 · Granted Sep 15, 2026

RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition

Inventors: Leo A. Kim (Boston, MA); Joseph F. Arboleda-Velasquez (Newton, MA); Dhanesh Amarnani (Allston, MA); Dean Eliott (Carlsbad, CA)
Assignee: Massachusetts Eye and Ear Infirmary
C12N15/113A61K9/0048A61K31/4025A61K31/5513A61K31/7105A61K45/06A61P27/02G01N33/6893C12N2310/14G01N2333/4706G01N2800/164
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,707
App. No.
18/351,320
Granted
Sep 15, 2026
Kind
B2
Abstract

The present subject matter provides compositions. formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.

Claims (25)

1 . A method for treating or reducing the severity of proliferative vitreoretinopathy (PVR) in a human subject comprising: diagnosing a PVR in a subject,

wherein said diagnosing a PVR comprises the steps of:

(a) providing an ocular test sample from said subject,

(b) assaying the level of RUNX1 protein or mRNA in the test sample; and

(c) diagnosing the subject as having aberrant PVR if the level of RUNX1 protein or mRNA is elevated in the test sample compared to a normal control; and

administering to the subject a small molecule RUNX1 inhibitor that comprises the structure of Formula I:

or a pharmaceutically acceptable salt or ester thereof, wherein

each R 1 is individually selected from halogen, alkyl, aryl, heteroaryl, or alkoxy,

and R 2 is selected from aryl or heteroaryl, and

a is 0 to 4;

Formula III:

or a pharmaceutically acceptable salt or ester thereof, wherein

each R 1 is individually selected from halogen, alkyl, aryl, heteroaryl, or alkoxy,

R 2 is selected from aryl or heteroaryl;

R 3 is alkyl or aryl, and

a is 0 to 4; or

Formula V:

or a pharmaceutically acceptable salt or ester thereof, wherein

R 1 is H 3 , NH 2 , or NHC (O) CH 3 , and

X is CH 2 or C(O).

2 . The method of claim 1 , wherein the test sample from the subject is an ocular sample obtained during ocular surgery.

3 . The method of claim 1 , wherein the level of RUNX1 protein is measured by ELISA, Western blot analysis, immunohistochemistry, or immunofluorescence.

4 . The method of claim 1 , wherein the level of RUNX1 mRNA is measured by Q-RT-PCR.

5 . The method of claim 1 , wherein the small molecule is Ro5-3335, Ro24-7429, or lenalidomide.

6 . The method of claim 1 , wherein the RUNX1 inhibitor is administered during or after intraocular surgery.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2025
From: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 071027/0028 →
CONFIRMATORY LICENSE Recorded Nov 25, 2024
From: UNIVERSITY OF COLORADO
To: UNITED STATES GOVERNMENT
Reel/Frame 069393/0223 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2023
From: KIM, LEO A.; ARBOLEDA-VELASQUEZ, JOSEPH F.; AMARNANI, DHANESH
To: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
Reel/Frame 064746/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2023
From: ELIOTT, DEAN
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 064732/0370 →
Continuity (3)
Continuation 16763880 · Nov 14, 2018
Provisional Application 62586067 · Nov 14, 2017
Related Publication 20240175022A1 · May 30, 2024
References Cited (388)
US 3405122A · Berger et al. · 1968 [cited by applicant]
US 4309404A · Deneale et al. · 1982 [cited by applicant]
US 4309406A · Guley et al. · 1982 [cited by applicant]
US 4521210A · Wong · 1985 [cited by applicant]
US 4556552A · Porter et al. · 1985 [cited by applicant]
US 4704295A · Porter et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4853224A · Wong · 1989 [cited by applicant]
US 4997652A · Wong · 1991 [cited by applicant]
US 5036101A · Hsu et al. · 1991 [cited by applicant]
US 5041438A · Hsu · 1991 [cited by applicant]
US 5141735A · Bellemin et al. · 1992 [cited by applicant]
US 5164188A · Wong · 1992 [cited by applicant]
US 5164376A · Hsu et al. · 1992 [cited by applicant]
US 5443505A · Wong et al. · 1995 [cited by applicant]
US 5501856A · Ohtori et al. · 1996 [cited by applicant]
US 5545806A · Lonbera et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonbera et al. · 1996 [cited by applicant]
US 5582981A · Toole et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonbera et al. · 1997 [cited by applicant]
US 5641673A · Haseloff et al. · 1997 [cited by applicant]
US 5641750A · Louis · 1997 [cited by applicant]
US 5641773A · Pardee et al. · 1997 [cited by applicant]
US 5661016A · Lonbera et al. · 1997 [cited by applicant]
US 5731005A · Ottoboni et al. · 1998 [cited by applicant]
US 5766242A · Wong et al. · 1998 [cited by applicant]
US 5824072A · Wong · 1998 [cited by applicant]
US 5837226A · Junaherr et al. · 1998 [cited by applicant]
US 5869079A · Wong et al. · 1999 [cited by applicant]
US 6074661A · Oleinik et al. · 2000 [cited by applicant]
US 6331313B1 · Wong et al. · 2001 [cited by applicant]
US 6369116B1 · Wong et al. · 2002 [cited by applicant]
US 6699493B2 · Wong · 2004 [cited by applicant]
US 6719971B1 · Carter et al. · 2004 [cited by applicant]
US 7354574B2 · Peyman · 2008 [cited by applicant]
US 7563906B2 · Hagihara et al. · 2009 [cited by applicant]
US 8053454B2 · Kearney et al. · 2011 [cited by applicant]
US 8293210B2 · Huana et al. · 2012 [cited by applicant]
US 8394826B2 · deLong et al. · 2013 [cited by applicant]
US 8414912B2 · Ciolino et al. · 2013 [cited by applicant]
US 8450344B2 · deLong et al. · 2013 [cited by applicant]
US 8484010B2 · Tuszynski et al. · 2013 [cited by applicant]
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 9023649B2 · Mali et al. · 2015 [cited by applicant]
US 9074199B1 · Chavez et al. · 2015 [cited by applicant]
US 9133269B2 · McConnell et al. · 2015 [cited by applicant]
US 9446048B2 · Liu et al. · 2016 [cited by applicant]
US 10562890B2 · Bushweller · 2020 [cited by applicant]
US 10828306B2 · Eliott et al. · 2020 [cited by applicant]
US 11229662B2 · Arboleda-Velasquez et al. · 2022 [cited by applicant]
US 11739326B2 · Kim · 2023 [cited by examiner]
US 20040229816A1 · Paris et al. · 2004 [cited by applicant]
US 20060034834A1 · Marasco et al. · 2006 [cited by applicant]
US 20060142193A1 · Wei et al. · 2006 [cited by applicant]
US 20060257452A1 · Hughes et al. · 2006 [cited by applicant]
US 20060264380A1 · Hellstrom et al. · 2006 [cited by applicant]
US 20070141066A1 · Phillips et al. · 2007 [cited by applicant]
US 20080014180A1 · Lanza et al. · 2008 [cited by applicant]
US 20080131484A1 · Robinson et al. · 2008 [cited by applicant]
US 20090203011A1 · Liebenberg et al. · 2009 [cited by applicant]
US 20090220488A1 · Gardner · 2009 [cited by applicant]
US 20090285786A1 · Zon et al. · 2009 [cited by applicant]
US 20100143380A1 · Crabb et al. · 2010 [cited by applicant]
US 20100233194A1 · Combal et al. · 2010 [cited by applicant]
US 20100330114A1 · Verdin et al. · 2010 [cited by applicant]
US 20110305641A1 · Kazlauskas et al. · 2011 [cited by applicant]
US 20120202793A1 · Sweetnam et al. · 2012 [cited by applicant]
US 20130156795A1 · Iavarone et al. · 2013 [cited by applicant]
US 20140004082A1 · Liu et al. · 2014 [cited by applicant]
US 20140249135A1 · Buraer et al. · 2014 [cited by applicant]
US 20150174138A1 · Bernstein et al. · 2015 [cited by applicant]
US 20170049760A1 · Schonbrunn et al. · 2017 [cited by applicant]
US 20170296617A1 · Schwartz et al. · 2017 [cited by applicant]
US 20180170939A1 · Accetta et al. · 2018 [cited by applicant]
US 20190350961A1 · Arboleda-Velasquez et al. · 2019 [cited by applicant]
US 20200102384A1 · Arboleda-Velasquez et al. · 2020 [cited by applicant]
US 20200103419A1 · Arboleda-Velasquez et al. · 2020 [cited by applicant]
US 20200375899A1 · Kim et al. · 2020 [cited by applicant]
US 20220341915A1 · Tata · 2022 [cited by applicant]
US 20230190959A1 · Arboleda-Velasquez · 2023 [cited by applicant]
US 20230310446A1 · Kim et al. · 2023 [cited by applicant]
EP 1163910 · 2001 [cited by applicant]
EP 1256574 · 2002 [cited by applicant]
EP 1270570 · 2003 [cited by applicant]
WO WO1993011161 · 1993 [cited by applicant]
WO WO1997023222 · 1997 [cited by applicant]
WO WO1999020620 · 1999 [cited by applicant]
WO WO1999064011 · 1999 [cited by applicant]
WO WO2001056988 · 2001 [cited by applicant]
WO WO2002053143 · 2002 [cited by applicant]
WO WO2002076976 · 2002 [cited by applicant]
WO WO2002076977 · 2002 [cited by applicant]
WO WO2002100833 · 2002 [cited by applicant]
WO WO2003078662 · 2003 [cited by applicant]
WO WO2003082808 · 2003 [cited by applicant]
WO WO2005074643 · 2005 [cited by applicant]
WO WO2007017065 · 2007 [cited by applicant]
WO WO2008015001 · 2008 [cited by applicant]
WO WO2008130315 · 2008 [cited by applicant]
WO WO2009146456 · 2009 [cited by applicant]
WO WO2009152901 · 2009 [cited by applicant]
WO WO2010104851 · 2010 [cited by applicant]
WO WO2011143484 · 2011 [cited by applicant]
WO WO2011163669 · 2011 [cited by applicant]
WO WO2012174419 · 2012 [cited by applicant]
WO WO2015049356 · 2015 [cited by applicant]
WO WO2016019165 · 2016 [cited by applicant]
WO WO2016025744 · 2016 [cited by applicant]
WO WO2016182904 · 2016 [cited by applicant]
WO WO2017112823 · 2017 [cited by applicant]
WO WO2017117538A1 · 2017 [cited by examiner]
WO WO2018183216 · 2018 [cited by applicant]
WO WO2019040448A1 · 2019 [cited by applicant]
WO WO2019221959 · 2019 [cited by applicant]
WO WO2021062412 · 2021 [cited by applicant]
WO WO2021216378 · 2021 [cited by applicant]
[No Author Listed], “Retinopathy of Prematurity,” American Association for Pediatric Ophthalmology and Strabismus, retrieved from URL<https://aapos.org/glossary/retinopathy-of-prematurity>, available on or before Apr. 2… [cited by applicant]
Ackermann et al., “Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19,” New England Journal of Medicine, Jul. 2020, 383(2):120-8. [cited by applicant]
Alder et al., “Diagnostic utility of telomere length testing in a hospital-based setting,” Proceedings of the National Academy of Sciences of the United States of America, Mar. 2018, 115(10):E2358-E2365. [cited by applicant]
Amarnani et al., “Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy,” Invest Ophthalmol Vis Sci., Aug. 2017, 58(10):3940-3949. [cited by applicant]
Antonetti et al., “Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1,” J Biol Chem., Aug. 1999, 274(33):23463-23467. [cited by applicant]
Arevalo et al., “Tractional Retinal Detachment Following Intravitreal Bevacizumab (Avastin) in Patients With Severe Proliferative Diabetic Retinopathy,” Br. J. Ophthalmol., Feb. 2008, 92(2):213-216. [cited by applicant]
Asato et al., “Comparison of gene expression profile of epiretinal membranes obtained from eyes with proliferative vitreoretinopathy to that of secondary epiretinal membranes,” PLoS One, 2013, 8(1):e54191, 8 pages. [cited by applicant]
Barberis et al., “Discovery of N-Substituted 7-Azaindoles as Pan-PIM Kinase Inhibitors—Lead Series Identification—Part II,” Bioorganic & Medicinal Chemistry Letters, Sep. 2017, 27(20):4735-4740. [cited by applicant]
Bataille et al., “Thiazolidine Derivatives as Potent and Selective Inhibitors of the PIM Kinase Family,” Bioorganic & Medicinal Chemistry, May 2017, 25(9):2657-2665. [cited by applicant]
Bataller and Brenner, “Liver fibrosis,” J Clin Invest., Feb. 2005, 15(2):209-18. [cited by applicant]
Beigel et al., “Remdesivir for the Treatment of Covid-19—Final Report,” New England Journal of Medicine, Nov. 2020, 383(19):1813-26, 14 pages. [cited by applicant]
Bellissimo et al., “Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling,” Blood Advances, Mar. 2020, 4(6):1145-58. [cited by applicant]
Belser et al., “Ocular tropism of respiratory viruses,” Microbiol Mol Biol Rev., Mar. 2013, 77(1):144-56. [cited by applicant]
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, Jan. 1977, 66(1):1-19. [cited by applicant]
Bergers et al., “Tumorigenesis and the Angiogenic Switch,” Nature Reviews Cancer, Jun. 2003, 3(6):401-410. [cited by applicant]
Blackwell et al., “Sequence-specific DNA Binding by the c-Myc Protein,” Science, Nov. 1990, 250(4984):1149-1151. [cited by applicant]
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes,” J. Immunol., Jul. 1991, 147(1):86-95. [cited by applicant]
Bonniaud et al., “Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-β-Mediated Pulmonary Fibrosis,” The Journal of Immunology, Aug. 2004, 173(3):2099, 11 pages. [cited by applicant]
Boyd, “Diabetic Retinopathy Diagnosis,” American Academy of Ophthamology, 2013, retrieved on Sep. 8, 2020, retrieved from URL <https://www.aao.org/eye-health/diseases/diabetic-retinopathy-diagnosis>, 6 pages. [cited by applicant]
Bravo et al., “The leukemia-associated AML1 (Runx1)-CBFbeta complex functions as a DNA-induced molecular clamp,” Nature Structural Biology, Apr. 2001, 8(4):371-8. [cited by applicant]
Burns et al., “Hematopoietic Stem Cell Fate Is Established by the Notch-Runx Pathway,” Genes & Development, Oct. 2005, 19(19):2331-2342. [cited by applicant]
Butko et al., “Complex regulation of HSC emergence by the Notch signaling pathway,” Dev. Biol., Jan. 2016, 409(1):129-138. [cited by applicant]
Castilla et al., “Failure of Embryonic Hematopoiesis and Lethal Hemorrhages in Mouse Embryos Heterozygous for a Knocked-In Leukemia Gene CBFB-MYH11,” Cell, Nov. 1996, 87(4):687-696. [cited by applicant]
Castoreno et al., “Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis,” Nat Chem Biol., Jun. 2010, 6(6):457-463, 21 pages (Author Manuscript). [cited by applicant]
Chang et al., “PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation,” Mol Cancer Ther., Sep. 2010, 9(9):2478-2487. [cited by applicant]
Cheema et al., “Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19),” Can J Ophthalmol., Aug. 2020, 55(4):e125-e129. [cited by applicant]
Cheloufi et al., “A Dicer-independent miRNA biogenesis pathway that requires Ago catalysis,” Nature, Jun. 2010, 465(7298):584-589. [cited by applicant]
Chen et al., “Intracellular Antibodies as a New Class of Therapeutic Molecules for Gene Therapy,” Human Gene Therapy, 1994, 5(5):595-601. [cited by applicant]
Chen et al., “Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease,” Br J Ophthalmol., Jun. 2020, 104(6):748-751. [cited by applicant]
Chen et al., “Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter,” Nature, Feb. 2009, 457(7231):887-891. [cited by applicant]
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., Aug. 1987, 196(4):901-917. [cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions,” Nature, Dec. 1989, 342:877-883. [cited by applicant]
Chung et al., “Developmental and Pathological Angiogenesis,” Annu. Rev. Cell Dev. Biol., Nov. 2011, 27:563-584. [cited by applicant]
Ciolino et al., “A drug-eluting contact lens,” Invest Ophthalmol Vis Sci., Jul. 2009, 50(7):3346-3352. [cited by applicant]
Cole, “Monoclonal Antibodies,” Can. Fam. Physician, 1987, 33:369-372. [cited by applicant]
Colyer et al., “Perforating globe injuries during operation Iraqi Freedom,” Ophthalmology, 2008, 115:2087-2093. [cited by applicant]
Connor et al., “Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis,” Nat Protoc., Oct. 2009, 4(11):1565-1573. [cited by applicant]
Cunningham et al., “Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction,” PNAS, Sep. 2012, 109(36):14592-14597. [cited by applicant]
Daxer, “The Fractal Geometry of Proliferative Diabetic Retinopathy: Implications for the Diagnosis and the Process of Retinal Vasculogenesis,” Current Eye Research, Dec. 1993, 12(12):1103-1109. [cited by applicant]
Delgado-Tirado et al., “Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy,” Scientific Reports, Nov. 2020, 10(1):20554, 15 pages. [cited by applicant]
Diabetes Control and Complications Trial Research Group, “The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial,” Diabete… [cited by applicant]
Dua et al., “The ocular surface as part of the mucosal immune system: conjunctival mucosa-specific lymphocytes in ocular surface pathology,” Eye (Lond.), 1995, 9(Pt 3):261-7. [cited by applicant]
Dubois et al., “Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme,” Am J Pathol., Jan. 2001, 158(1):305-16. [cited by applicant]
Eapen et al., “Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?,” European Respiratory Journal, Oct. 2020, 56(4):2003167, 3 pages. [cited by applicant]
Edgar et al., “Gene Expression Omnibus: NCBI gene expression and hybridization array data repository,” Nucleic Acids Research, Jan. 2002, 30(1):207-210. [cited by applicant]
Elbashir et al., “Functional anatomy of siRNAs for mediating efficient RNAi in [cited by applicant]
Eliott et al., “Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment,” Retina, 2017, 37(7):1229-1235. [cited by applicant]
Espinoza et al., “Notch Inhibitors for Cancer Treatment,” Pharmacol Ther., Aug. 2013, 139(2):95-110. [cited by applicant]
Extended European Search Report in European Application No. 17871449.9, dated May 25, 2020, 13 pages. [cited by applicant]
Extended European Search Report in European Appln. No. 18878909.3, dated Jul. 22, 2021, 7 pages. [cited by applicant]
Eye.Hms.Harvard.edu [online], “Harvard Medical School Dept. of Ophthalmology Home/News,” Apr. 2017, retrieved on Dec. 10, 2021, retrieved from URL<https://eye.hms.harvard.edu/news/researchers-identify-new-target-abnorma… [cited by applicant]
Fehniger et al., “Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13,” Blood, 2009, 113(5):1002-1005. [cited by applicant]
Fire et al., “Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans,” Nature, 1998, 391:806-810. [cited by applicant]
Fishwild et al., “High-Avidity Human IgG Kappa Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice,” Nature Biotechnology, Aug. 1996, 14(7):845-851. [cited by applicant]
Frangogiannis, “Fibroblast-Extracellular Matrix Interactions in Tissue Fibrosis,” HHS Public Access Author Manuscript, doi:10.1007/s40139-016-0099-1, published online Feb. 5, 2016, 14 pages; Published in final edited fo… [cited by applicant]
Fràter-Schröder et al., “Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo,” Proc Natl Acad Sci USA, Aug. 1987, 84(15):5277-81. [cited by applicant]
Friedlander, “Fibrosis and diseases of the eye,” J Clin Invest., 2007, 117(3):576-586. [cited by applicant]
Fu et al., “The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPγS-, and phorbol ester-induced Ca [cited by applicant]
Geback et al., “TScratch: A novel and simple software tool for automated analysis of monolayer wound healing assays,” Biotechniques, Apr. 2009, 46(4):265-274. [cited by applicant]
GenBank Accession No. AAI41856.1, “Pim-3 oncogene [ [cited by applicant]
GenBank Accession No. AB114795.1, “ [cited by applicant]
GenBank Accession No. AK292005.1, “ [cited by applicant]
GenBank Accession No. BAD42438.1, “serine/threonine kinase Pim-3 [ [cited by applicant]
GenBank Accession No. BAF84694.1, “Unnamed protein product [ [cited by applicant]
GenBank Accession No. BC141855.1, “ [cited by applicant]
GenBank Accession No. NM_000598.4, “ [cited by applicant]
GenBank Accession No. NM_001001852.4, “ [cited by applicant]
GenBank Accession No. NM_001001890.2, “ [cited by applicant]
GenBank Accession No. NM_001013398.1, “ [cited by applicant]
GenBank Accession No. NM_001122607.2, “ [cited by applicant]
GenBank Accession No. NM_001754.4, “ [cited by applicant]
GenBank Accession No. NP_000589.2, “Insulin-like growth factor-binding protein 3 isoform b precursor [ [cited by applicant]
GenBank Accession No. NP_001013416.1, “Insulin-like growth factor-binding protein 3 isoform a precursor [ [cited by applicant]
GenBank Accession No. XM_005261068.3, “Predicted: [cited by applicant]
GenBank Accession No. XM_005261069.4, “Predicted: [cited by applicant]
GenBank Accession No. XM_011529766.2, “Predicted: [cited by applicant]
GenBank Accession No. XM_011529768.2, “Predicted: [cited by applicant]
GenBank Accession No. XM_011529770.2, “Predicted: [cited by applicant]
GenBank Accession No. XM_017028487.1, “Predicted: [cited by applicant]
GenBank Accession No. XR_937576.2, “Predicted: [cited by applicant]
George et al., “Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy,” The Lancet Respiratory Medicine, Aug. 2020, 8(8):807-15. [cited by applicant]
ghr.nlm.nih.gov [online], “Age-related macular degeneration,” Aug. 2016, retrieved from URL <https://ghr.nlm.nih.gov/condition/age-related-macular-degeneration>, 8 pages. [cited by applicant]
Giani et al., “In Vivo Evaluation of Laser-Induced Choroidal Neovascularization Using Spectral-Domain Optical Coherence Tomography,” Investigative Ophthalmology & Visual Science, 2011, 52(6):3880-3887. [cited by applicant]
Glinsky, “Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-… [cited by applicant]
Graney and Lee, “Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives,” Patient Relat Outcome Meas., 2018, 9:321-8. [cited by applicant]
Haghjou et al., “Sustained release intraocular drug delivery devices for treatment of uveitis,” J Ophthalmic Vis Res., Oct. 2011, 6(4):317-329. [cited by applicant]
Hakeem et al., “Retinopathy of Prematurity: A Study of Prevalence and Risk Factors,” Middle East African Journal of Ophthalmology, 2012, 19(3):289-294. [cited by applicant]
Harris et al., “Glucose Metabolism Impacts the Spatiotemporal Onset and Magnitude of HSC Induction in Vivo,” Blood, Mar. 2013, 121(13):2483-2493. [cited by applicant]
Haubrich et al., “A Randomized Trial of the Activity and Safety of Ro 24-7429 (Tat Antagonist) Versus Nucleoside for Human Immunodeficiency Virus Infection,” The Journal of Infectious Diseases, Nov. 1995, 172(5): 1246-1… [cited by applicant]
Heckl et al., “Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing,” Nat. Biotechnol., 2014, 32(9):941-946, 14 pages. [cited by applicant]
Hendren et al., “Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome,” Circulation, Apr. 2020, 141(23):1903-1914, 19 pages. [cited by applicant]
Hiscott et al., “Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC),” Eye (Lond)., Jul. 2002, 16(4):393-403. [cited by applicant]
Hiscott et al., “Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study,” Br J Ophthalmol., Oct. 1984, 68(10):708-15. [cited by applicant]
Holliger et al., “‘Diabodies’: Small Bivalent and Bispecific Antibody Fragments,” Proceedings of the National Academy of Sciences of the United States of America, Jul. 1993, 90(14):6444-6448. [cited by applicant]
Hong et al., “Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition,” Oncotarget, Mar. 2017, 8(11):17610-17627. [cited by applicant]
Hoogenboom et al., “By-Passing immunisation: Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,” Journal of Molecular Biology, Sep. 1992, 227(2):381-388. [cited by applicant]
Hoyt et al., “Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice,” J Pharmacol Exp Ther., Aug. 1988, 246(2):765-71. [cited by applicant]
Hsu et al., “Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF Era”, Journal of Ophthalmology, Jun. 2014, Article ID 917375, 2014(7):11 pages. [cited by applicant]
Hsu et al., “Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro,” Proc Natl Acad Sci USA, Jun. 1993, 90(14):6395-9. [cited by applicant]
Huang et al., “Bioinformatics Enrichment Tools: Paths Toward the Comprehensive Functional Analysis of Large Gene Lists,” Nucleic Acids Research, Jan. 2009, 37(1):1-13. [cited by applicant]
Huertas et al., “Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?,” European Respiratory Journal, Jul. 2020, 56(1):2001634, 5 pages. [cited by applicant]
Hutchinson et al., “Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review,” European Respiratory Journal, Sep. 2015, 46(3):795-806. [cited by applicant]
Ikenoya et al., “Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor,” J. Neurochem., Apr.… [cited by applicant]
Illendula et al., “Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers,” EBioMedicine, Nov. 2017, 8:117-131. [cited by applicant]
Imanirad et al., “HIF1α is a Regulator of Hematopoietic Progenitor and Stem Cell Development in Hypoxic Sites of the Mouse Embryo,” Stem Cell Res., Jan. 2014, 12(1):24-35. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2017/061620, dated May 21, 2019, 17 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2018/061110, dated May 28, 2020, 12 pages. [cited by applicant]
International Search Report and the Written Opinion in International Appln. No. PCT/US2018/061110, dated Mar. 25, 2019, 17 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/027798, dated Sep. 28, 2021, 13 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/049322, dated Feb. 8, 2022, 12 pages. [cited by applicant]
International Search Report in International Appln. No. PCT/US2017/061620, dated Mar. 19, 2018, 24 pages. [cited by applicant]
Ishikawa et al., “Microarray Analysis of Gene Expression in Fibrovascular Membranes Excised From Patients With Proliferative Diabetic Retinopathy,” Investigative Ophthalmology & Visual Science, Feb. 2015, 56(2):932-946. [cited by applicant]
Ishizaki et al., “Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases,” Mol Pharmacol., May 2000, 57(5):976-83. [cited by applicant]
Ito et al., “RUNX Transcription Factors as Key Targets of TGF-beta Superfamily Signaling,” Current Opinion in Genetics and Development, Feb. 2003, 13(1):43-47. [cited by applicant]
Iwatsuki et al., “Runx1 Promotes Angiogenesis by Downregulation of Insulin-Like Growth Factor-Binding Protein-3”, Oncogene, Feb. 2005, 24(7):1129-1137. [cited by applicant]
Ji et al., “Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers,” Proceedings of the National Academy of Sciences, May 2019, 116(19):9453-9462. [cited by applicant]
Jo et al., “Animal Models of Diabetic Retinopathy: Doors to Investigate Pathogenesis and Potential Therapeutics,” Journal of Biomedical Science, 2013, 20:38, 13 pages. [cited by applicant]
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse,” Nature, May 1986, 321(6069):522-525. [cited by applicant]
Joyce, “Amplification, Mutation and Selection of Catalytic RNA,” Gene, Oct. 1989, 82(1):83-87. [cited by applicant]
Kalev-Zylinska et al., “Runx1 is Required for Zebrafish Blood and Vessel Development and Expression of a Human RUNX1-CBF2T1 Transgene Advances a Model for Studies of Leukemogenesis,” Development, 2002, 129(8):2015-2030. [cited by applicant]
Kategaya et al., “USP7 Small-Molecule Inhibitors Interfere With Ubiquitin Binding,” Nature, Oct. 2017, 550(7677):534-538, 33 pages. [cited by applicant]
Kim et al., “A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis,” The American Journal of Pathology, 2012, 181(2):376-379. [cited by applicant]
Kim et al., “Characterization of Cells from Patient-Derived Fibrovascular Membranes in Proliferative Diabetic Retinopathy,” Molecular Vision, Jun. 2015, 21:673-687. [cited by applicant]
Kim et al., “Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging,” Invest. Ophthalmol. Vis. Sci., Aug. 2004, 45(8):2722-2731. [cited by applicant]
Kim et al., “Inhibition of Runx1 by the Ro5-3335 benzodiazepine derivative reduces aberrant retinal angiogenesis,” Abstract, Presented at Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)… [cited by applicant]
Kim et al., “Pim-1 Kinase Phosphorylates and Stabilizes RUNX3 and Alters Its Subcellular Localization,” Journal of Cellular Biochemistry, Nov. 2008, 105(4):1048-1055. [cited by applicant]
Kim et al., “RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation,” Proc Natl Acad Sci USA, Nov. 2014, 111(46):16389-94. [cited by applicant]
Kita et al., “Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target,” Proceedings of the National Academy of Science, Nov. 2008, 105(45):17504-17509. [cited by applicant]
Knipe et al., “The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis,” Pharmacol Rev., Jan. 2015, 67(1):103-117. [cited by applicant]
Köhler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature, Aug. 1975, 256(5517):495-497. [cited by applicant]
Korol et al., “RhoA/ROCK signaling regulates TGFβ-induced epithelial-mesenchymal transition of lens epithelial cells through MRTF-A,” Mol Med., Dec. 2016, 22:713-723. [cited by applicant]
Kozlowski et al., “A Human Melanoma Line Heterogeneous With Respect to Metastatic Capacity in Athymic Nude Mice,” Journal of the National Cancer Institute, Apr. 1984, 72(4):913-917. [cited by applicant]
Kuiper et al., “The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy,” PLoS ONE, Jul. 2008, 3(7):e2675, 7 pages. [cited by applicant]
Lam et al., “Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis,” Diabetes, 2017, 66:1950-1956. [cited by applicant]
Lederer et al., “Idiopathic Pulmonary Fibrosis,” New England Journal of Medicine, May 2018, 378(19):1811-23. [cited by applicant]
Lee et al., “TGF-β regulates cell fate during epithelial-mesenchymal transition by upregulating survivin,” Cell Death & Disease, Jul. 2013, 4(7):e714, 10 pages. [cited by applicant]
Li et al., “RUNX1 promotes tumour metastasis by activating the WNT/beta-catenin signalling pathway and EMT in colorectal cancer,” J Exp Clin Cancer Res, Aug. 2019, 38(1):334, 13 pages. [cited by applicant]
Liang et al., “In Vitro Scratch Assay: A Convenient and Inexpensive Method for Analysis of Cell Migration in Vitro,” Nature Protocols, Mar. 2007, 2(2):329-333. [cited by applicant]
Liao et al., “Rho kinase (ROCK) inhibitors,” J Cardiovasc Pharmacol, Jul. 2007, 50(1):17-24. [cited by applicant]
Liberati et al., “Smads bind directly to the Jun family of AP-1 transcription factors,” Proc Natl Acad Sci USA, Apr. 1999, 96(9):4844-9. [cited by applicant]
Lichtinger et al., “Chromatin Regulation by RUNX1,” Blood Cells, Molecules and Diseases, Apr. 2010, 44(4):287-290. [cited by applicant]
Lie-A-Ling et al., “RUNX1 Positively Regulates a Cell Adhesion and Migration Program in Murine Hemogenic Endothelium Prior to Blood Emergence,” Blood, Sep. 2014, 124(11):e11-e20. [cited by applicant]
Lin et al., “Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma,” J Ocul Pharmacol Ther., 2018, 34(1-2):40-51. [cited by applicant]
Lin et al., “LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1,” Cell Death & Disease, Aug. 2020, 11(8):706, 14 pages. [cited by applicant]
Liu et al., “Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract,” Med Virol., Sep. 2020, 92(9):1410-1412. [cited by applicant]
Lofqvist et al., “IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth,” PNAS, 2007, 104(25):10589-10594. [cited by applicant]
Lonberg et al., “Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications,” Nature, Apr. 1994, 368:856-859. [cited by applicant]
Lonberg et al., “Human Antibodies from Transgenic Mice,” Intern. Rev. Immunol., 1995, 13(1):65-93. [cited by applicant]
Lucas et al., “Abstract: Formation of abdominal adhesions is inhibited by antibodies to transforming growth factor-beta 1,” J Surg Res., Oct. 1996, 65(2):135-8, 4 pages. [cited by applicant]
Ludwig, “The Use of Mucoadhesive Polymers in Ocular Drug Delivery,” Advanced Drug Delivery Reviews, 2005, 57(11):1595-1639. [cited by applicant]
Maher, “PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery,” European Respiratory Review, Jun. 2013, 22(128):148-52. [cited by applicant]
Malaviya et al., “Anti-TNFα therapy in inflammatory lung diseases,” HHS Public Access Author Manuscript, doi:10.1016/j.pharmthera.2017.06.008, published online Nov. 4, 2017, 23 pages; Published in final edited form as: … [cited by applicant]
Malaviya et al., “Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-α Antibody,” Toxicological Sciences, Nov. 2015, 148(1):71-88. [cited by applicant]
Marks et al., “By-Passing Immunization: Human Antibodies from V-Gene Libraries Displayed on Phage,” J. Mol. Biol., Dec. 1991, 222(3):581-597. [cited by applicant]
Martin et al., “TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target?,” Int J Radiat Oncol Biol Phys., May 2000, 47(2):277-90. [cited by applicant]
Martines et al., “Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Corona virus Disease, United States,” Emerg Infect Dis., Sep. 2020, 26(9):2005-15. [cited by applicant]
Martinez-Hoyer et al., “RUNX1 Loss of Function Drives Resistance to Lenalidomide in Del(5Q) Myelodysplastic Syndrome Patients,” Leukemia Research, 2017, 1(55):S43-S44. [cited by applicant]
Masoumpour et al., “Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering Surgeries,” Open Ophthalmol J., 2016, 10:68-85. [cited by applicant]
mayoclinic.org [online], “Diabetic Retinopathy,” Mar. 2015, via Internet archive: Wayback Machine URL <http://web.archive.org/web/20180308085607/https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/diagno… [cited by applicant]
mayoclinic.org [online], “Dry Macular Degeneration,” 2015, retrieved from URL <https://www.mayoclinic.org/diseasesconditions/drymaculardegeneration/diagnosis-treatment/drc-20350381>, 5 pages. [cited by applicant]
mayoclinic.org [online], “Wet Macular Degeneration,” 2015, retrieved from URL <https://www.mayoclinic.org/diseasesconditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113>, 6 pages. [cited by applicant]
McAuley et al., “Vitreous Biomarkers in Diabetic Retinopathy: A Systematic Review and Meta-Analysis,” Journal of Diabetic Complications, 2014, 28(3):419-425. [cited by applicant]
McLeod et al., “From Blood Islands to Blood Vessels: Morphologic Observations and Expression of Key Molecules during Hyaloid Vascular System Development,” Investigative Ophthalmology & Visual Science, Dec. 2012, 53(13):… [cited by applicant]
Medlineplus.gov [online], “Retinal vein occlusion,” Available on or before Mar. 6, 2018, retrieved Feb. 22, 2019, retrieved from URL <https://medlineplus.gov/ency/article/007330.htm>, 4 pages. [cited by applicant]
Michaud et al., “Integrative Analysis of RUNX1 Downstream Pathways and Target Genes,” BMC Genomics, Jul. 2008, 9:363, 17 pages. [cited by applicant]
Morrison, “Success in Specification,” Nature, Apr. 1994, 368:812-813. [cited by applicant]
Moshfeghi et al., “Retinal Capillary Angioma,” American Academy of Ophthalmology, Oct. 2013, 7 pages. [cited by applicant]
Moshirfar et al., “Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature,” Med Hypothesis Discov Innov Ophthalmol., Fall 2018, 7(3):101-111. [cited by applicant]
Mukhopadhyay et al., “Role of TNFα in pulmonary pathophysiology,” Respiratory Research, 2006, 7(1):125, 9 pages. [cited by applicant]
my.clevelandclinic.org [online], “Retinal Vein Occlusion (RVO),” 2015, retrieved from URL <https://my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo>, 4 pages. [cited by applicant]
Nakano et al., “Design and Synthesis of an in Vivo-Efficacious PIM3 Kinase Inhibitor as a Candidate Anti-Pancreatic Cancer Agent,” Bioorganic & Medicinal Chemistry Letters, Dec. 2015, 25(24):5687-5693. [cited by applicant]
Namba et al., “Indispensable Role of the Transcription Factor PEBP2/CBF in Angiogenic Activity of a Murine Endothelial Cell MSS31,” Oncogene, Jan. 2000, 19(1):106-114. [cited by applicant]
nei.nih.gov [online], “Facts About Retinopathy of Prematurity (ROP),” National Eye Institute, available on or before Jun. 2014, retrieved on Feb. 22, 2019, retrieved from URL <https://nei.nih.gov/health/rop/rop>, 3 page… [cited by applicant]
Neuberger, “Generating High-Avidity Human Mabs in Mice,” Nature Biotechnology, Jul. 1996, 14(7):826, 1 page. [cited by applicant]
Nicholls et al., “An Improved Method for Generating Single-Chain Antibodies From Hybridomas,” Journal of Immunological Methods, Sep. 1993, 165(1):81-91. [cited by applicant]
Office Action in Australian Appln. No. 2018369784, dated Nov. 8, 2022, 4 pages. [cited by applicant]
Office Action in European Appln. No. 17871449.9, dated Jul. 5, 2022, 15 pages. [cited by applicant]
Office Action in Japanese Appln. No. 2020-544393, dated Nov. 14, 2022, 8 pages (with English translation). [cited by applicant]
O'Hare et al., “Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators,” The American Journal of Pathology, Jul… [cited by applicant]
Ojo et al., “Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies,” Pulmonary Medicine, Aug. 2020, 2020:6175964, 10 pages. [cited by applicant]
Palakurthi et al., “Investigation of kinetics of methotrexate for therapeutic treatment of intraocular lymphoma,” Current Eye Research, Oct. 2010, 35(12):1105-1115. [cited by applicant]
Pandya et al., “Neovascular Glaucoma,” Medscape, available on or before Oct. 2016, retrieved from URL <https://emedicine.medscape.com/article/1205736-overview#a6>, 15 pages. [cited by applicant]
Pashaei et al., “Immunotherapy for SARS-CoV-2: potential opportunities,” Expert Opin Biol Ther., Oct. 2020, 20(10):1111-5. [cited by applicant]
Pettus et al., “Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors,” J. Med. Chem., Jun. 2016, 59(13):6407-6430. [cited by applicant]
Pluckthun, “Antibodies from [cited by applicant]
Polak et al., “A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression,” Mod Pathol., Nov. 2020, 33(11):2128-38. [cited by applicant]
Pratt et al., “Abstract 1010: Identification of evolutionarily conserved transcription response elements associated with regulation of cadherin expression in retinal pigment epithelial cells,” Molecular Biology of the C… [cited by applicant]
Presta, “Antibody Engineering,” Current Opinion in Structural Biology, 1992, 2(4):593-596. [cited by applicant]
Rakoczy et al., “Characterization of a Mouse Model of Hyperglycemia and Retinal Neovascularization,” The American Journal of Pathology, Nov. 2010, 177(5):2659-2670. [cited by applicant]
Ran et al., “γ-Secretase Inhibitors in Cancer Clinical Trials are Pharmacologically and Functionally Distinct,” EMBO Molecular Medicine, Jul. 2017, 9(7):950-966. [cited by applicant]
Riddell et al., “RUNX1: an emerging therapeutic target for cardiovascular disease,” Cardiovasc Res., Mar. 2020, 116(8):1410-1423. [cited by applicant]
Riechmann et al., “Reshaping Human Antibodies for Therapy,” Nature, Mar. 1988, 332:323-327. [cited by applicant]
Robert et al., “A Drug Delivery System for Administration of Anti-TNF-α Antibody,” Transl Vis Sci Technol., Mar. 2016, 5(2):11, 11 pages. [cited by applicant]
Sainson et al., “TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype,” Blood, May 2008, 111(10):4997-5007. [cited by applicant]
Saint-Geniez et al., “Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Muller Cells and Photoreceptors,” PLoS ONE, Nov. 2008, 3(11):e3554, 13 pages. [cited by applicant]
Sang et al., “Is Blockade of Vascular Endothelial Growth Factor Beneficial for all Types of Diabetic Retinopathy?” Diabetologia, Jul. 2008, 51(9): 1570-1573. [cited by applicant]
Schaefer et al., “In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19,” Modern Pathology, Jun. 2020, 33(11):2104-14. [cited by applicant]
Scholle, “Ocular Ischemic Syndrome,” Medscape, 2019, retrieved Sep. 8, 2020, retrieved from URL <https://emedicine.medscape.com/article/1201678-overview>, 3 pages. [cited by applicant]
Selman et al., “Idiopathic pulmonary fibrosis: an epithelial fibroblastic cross-talk disorder,” Respir Res., 2002, 3(1):3, 8 pages. [cited by applicant]
Shah et al., “Alk5/Runx1 signaling mediated by extracellular vesicles promotes vascular repair in acute respiratory distress syndrome,” Clin Transl Med, Jun. 2018, 7(1):19, 18 pages. [cited by applicant]
Shaki-Loewenstein et al., “A universal strategy for stable intracellular antibodies”, Journal of Immunological Methods, Aug. 2005, 303(1-2):19-39. [cited by applicant]
Shao et al., “Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis,” PLoS ONE, Jul. 2013, 8(7):e69552, 11 pages. [cited by applicant]
Shaw et al., “Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury,” Exp Eye Res., May 2017, 158:33-42, 19 pages. [cited by applicant]
Shazly et al., “Neovascular Glaucoma: Etiology, Diagnosis and Prognosis,” Seminars in Ophthalmology, Mar. 2009, 24(2):113-121. [cited by applicant]
Shen et al., “Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays,” Scientific Reports, Nov. 2015, 5:16749, 14 pages. [cited by applicant]
Shen et al., “Isolation and Culture of Primary Mouse Retinal Pigment Epithelial (RPE) Cells with Rho-Kinase and TGFβR-1/ALK5 Inhibitor,” Med Sci Monit., Dec. 2017, 23:6132-6136. [cited by applicant]
Sinha and Ware, “Selective tumour necrosis factor receptor-1 inhibition in acute lung injury: a new hope or a false dawn?,” Thorax, Aug. 2018, 73(8):699-701. [cited by applicant]
Smith et al., “Oxygen-Induced Retinopathy in the Mouse,” Invest Ophthalmol Vis Sci, Jan. 1994, 35(1):101-111. [cited by applicant]
Sohn et al., “Angiofibrotic Response to Vascular Endothelial Growth Factor Inhibition in Diabetic Retinal Detachment,” Arch Ophthalmol, Sep. 2012, 130(9):1127-1134. [cited by applicant]
Strongman et al., “Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK,” Adv Ther., May 2018, 35(5):724-36. [cited by applicant]
Sui et al., “oPOSSUM: Identification of Over-represented Transcription Factor Binding Sites in Co-Expressed Genes,” Nucleic Acids Research, 2005, 33(10):3154-3164. [cited by applicant]
Taheri et al., “Nanoparticles of conjugated methotrexate-human serum albumin: preparation and cytotoxicity evaluations” J Nanomaterials, Jan. 2011, 2011:768201, 7 pages. [cited by applicant]
Tang et al., “Runt-Related Transcription Factor 1 Regulates LPS-Induced Acute Lung Injury via NF-κB Signaling,” Am J Respir Cell Mol Biol., 2017, 57(2):174-83. [cited by applicant]
Tashiro et al., “Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis,” Frontiers in Medicine, Jul. 2017, 4:118, 11 pages. [cited by applicant]
Terelak-Borys et al., “Ocular Ischemic Syndrome—A Systematic Review,” Med Sci Monit, Aug. 2012, 18(8):RA138-RA144. [cited by applicant]
The RECOVERY Collaborative Group, “Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report,” New England Journal of Medicine, Feb. 2021, 384(8):693-704, 11 pages. [cited by applicant]
Thomas, “Furin at the cutting edge: from protein traffic to embryogenesis and disease,” HHS Public Access Author Manuscript, doi: 10.1038/nrm934, published online 2002, 32 pages; Published in final edited form as Nat Re… [cited by applicant]
Tober et al., “Taking the leap: Runx1 in the formation of blood from endothelium,” Current Topics in Developmental Biology, Feb. 2016, 118:113-162. [cited by applicant]
Trapnell et al., “TopHat: Discovering Splice Junctions with RNA-Seq,” Bioinformatics, Apr. 2009, 25(9):1105-1111. [cited by applicant]
Tuerk et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase,” Science, Aug. 1990, 249(4968):505-510. [cited by applicant]
Turell et al., “Vascular Tumors of the Retina and Choroid: Diagnosis and Treatment,” Middle East Afr J Ophthalmol., 2010, 17(3):191-200. [cited by applicant]
Ulrich et al. “CD147 as a Target for COVID-19 Treatment: Suggested Effects 2, 4-6, 19, 21-23 of Azithromycin and Stem Cell Engagement,” Stem Cell Reviews and Reports, Apr. 2020, 16:434-440, 7 pages. [cited by applicant]
UniProt Accession No. P17936, “Insulin-like growth factor-binding protein 3,” Nov. 1, 1990, 8 pages. [cited by applicant]
UniProt Accession No. Q01196-10, “Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-11, “RUNX1_HUMAN Isoform AML-1L of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-2, “RUNX1_Human Isoform AML-1A of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-3, “RUNX1_Human Isoform AML-1C of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-4, “RUNX1_Human Isoform AML-1E of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-5, “RUNX1_HUMAN Isoform AML-1FA of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-6, “RUNX1_HUMAN Isoform AML-1FB of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-7, “RUNX1_HUMAN Isoform AML-1FC of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-8, “RUNX1_Human Isoform AML-1G of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q01196-9, “RUNX1_HUMAN Isoform AML-1H of Runt-related transcription factor 1,” Apr. 1, 1993, 1 page. [cited by applicant]
UniProt Accession No. Q86V86, “Serine/threonine-protein kinase pim-3,” Nov. 21, 2003, 6 pages. [cited by applicant]
Van Geest et al., “A Shift in the Balance of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor by Bevacizumab Causes the Angiofibrotic Switch in Proliferative Diabetic Retinopathy,” Br J Ophthalmol,… [cited by applicant]
Vancheri et al., “Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial,” Am J Respir Crit Care Med., Feb. 2018, 197(3):356-63. [cited by applicant]
Velez and Whitcup, “New developments in sustained release drug delivery for the treatment of intraocular disease,” Br J Ophthalmol, 1999, 83:1225-1229. [cited by applicant]
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, Mar. 1988, 239(4847):1534-1536. [cited by applicant]
Vijayaragavan et al., “Controlled Release of Methotrexate Using Alpha-Lactalbumin Microparticles,” Int J Pharm Res, 2011, 3(1):39-44. [cited by applicant]
Wang et al. “Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor With Optimized Bioavailability,” J. Med. Chem., Apr. 2017, 60(10):4458-4473. [cited by applicant]
Whitmore et al., “TNF-α signaling regulates RUNX1 function in endothelial cells,” The FASEB Joumal, Feb. 2021, 35(2):e21155, 17 pages. [cited by applicant]
Wikipedia.org [online], “Rho kinase inhibitor,” last updated Feb. 20, 2023, retrieved on Mar. 14, 2023, retrieved from URL<https://en.wikipedia.org/wiki/Rho_kinase_inhibitor>, 5 pages. [cited by applicant]
Wu et al., “Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China,” JAMA Ophthalmol., May 2020, 138(5):575-578. [cited by applicant]
Wu et al., “The ROCK inhibitor, thiazovivin, inhibits human corneal endothelial-to-mesenchymal transition/epithelial-to-mesenchymal transition and increases ionic transporter expression,” Int J Mol Med., Oct. 2017, 40(4… [cited by applicant]
Xie et al., “Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis,” Cell Rep., Mar. 2018, 22(13):3625-40. [cited by applicant]
Yadav et al., “Tumour Angiogenesis and Angiogenic Inhibitors: A Review,” J Clin Diagn Res., Jun. 2015, 9(6):XE01-XE05. [cited by applicant]
Yamaguchi et al., “Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases,” J Ophthalmol., 2017, 2017:8543592, 8 pages. [cited by applicant]
Yan et al., “Feedback regulation of TGF-β signaling,” Acta Biochimica et Biophysica Sinica, Jan. 2018, 50(1):37-50. [cited by applicant]
Yang et al., “Mechanisms of epithelial—mesenchymal transition in proliferative vitreoretinopathy,” Discov Med., Oct. 2015, 20(110):207-217, 21 pages. [cited by applicant]
Yarrow et al., “Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor,” Chem. Biol., Mar. 2005, 12(3):385-395. [cited by applicant]
Yoshida et al., “Gene expression profile of fibrovascular membranes from patients with proliferative diabetic retinopathy,” Br J Ophthalmol., 2010, 94(6):795-801. [cited by applicant]
Yuan et al., “Notch Signaling: An Emerging Therapeutic Target for Cancer Treatment,” Cancer Letters, Dec. 2015, 369(1):20-27. [cited by applicant]
Yue et al., “TGF-β: Titan of Lung Fibrogenesis,” HHS Public Access Author Manuscript, doi: 10.2174/10067, Oct. 2013, 20 pages; Published in final edited form as: Curr Enzym Inhib., Jul. 2010, 6(2):10.2174/10067. [cited by applicant]
Yzaguirre et al., “The Role of Runx1 in Embryonic Blood Cell Formation,” RUNX Proteins in Development and Cancer, Singapore: Springer Singapore, Groner et al. (eds.), 2017, pp. 47-64. [cited by applicant]
Zapata et al., “Engineering Linear F(ab′)2 Fragments for Efficient Production in [cited by applicant]
Zhou et al., “Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-f3-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ,” EBioMedicine, May 2018, 31:2… [cited by applicant]
Zhou et al., “RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation,” Leukemia, 2019, 33:2006-2021. [cited by applicant]
Zhou et al., “Sustained subconjunctival delivery of infliximab protects the cornea and retina following alkali burn to the eye,” Invest Ophthalmol Vis Sci., Jan. 2017, 58(1):96-105. [cited by applicant]
Notice of Allowance in Japanese Appln. No. 2020-544393, dated Dec. 14, 2023, 6 pages (with English translation). [cited by applicant]
Office Action in European Appln. No. 18878909.3, mailed on Apr. 4, 2025, 4 pages. [cited by applicant]
Office Action in Canadian Appln. No. 3,082,643, mailed on Dec. 2, 2024, 5 pages. [cited by applicant]
Huang et al., “Kidney fibrosis: from mechanisms to therapeutic medicines,” Signal Transduction and Targeted Therapy, Mar. 2023, 8(1):129, 20 pages. [cited by applicant]
Illendula et al., “A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice,” Science, Feb. 2015, 347(6223):779-84. [cited by applicant]
MedicalNewsToday.com [online], “What is pulmonary fibrosis?,” Jan. 2023, retrieved on Jul. 23, 2025, retrieved from URL <https://www.medicalnewstoday.com/articles/pulmonary-fibrosis>, 15 pages. [cited by applicant]
My.ClevelandClinic.org [online], “Pulmonary Fibrosis,” May 2025, retrieved on Jul. 23, 2025, retrieved from URL, <https://my.clevelandclinic.org/health/diseases/10959-pulmonary-fibrosis>, 13 pages. [cited by applicant]
News. Vumc.org [online], “VUMC team finds potential treatment for kidney fibrosis,” Mar. 2024, retrieved on Jul. 23, 2025, retrieved from URL <https://news.vumc.org/2024/03/25/vumc-team-finds-potential-treatment-for-kid… [cited by applicant]
Trujillo et al., “Angiogenesis in acute myeloid leukemia and opportunities for novel therapies,” Journal of Oncology, 2012; 2012(1):128608, 9 pages. [cited by applicant]
Zhang et al., “Treatment of liver fibrosis: Past, current, and future,” World journal of Hepatology, Jun. 2023, 15(6):755, 21 pages. [cited by applicant]
Kaelin “Use and abuse of RNAi to study mammalian gene function,” Science, Jul. 2012, 337(6093):421-422, 4 pages (Author Manuscript). [cited by applicant]
Weiss et al., “Recognizing and exploiting differences between RNAi and small-molecule inhibitors,” Nature Chemical Biology, Dec. 2007, 3(12):739-744, 12 pages (Author Manuscript). [cited by applicant]